In accordance with a decision made by the Annual General Meeting held on May 15, 2014, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2014, and the Chairman of the Board.
For the 2015 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:
Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Lennart Johansson, Investor
Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals for the Board of Directors that are to be presented to and decided upon at the Annual General Meeting on June 11, 2015.
Lund, December 9, 2014
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit www.activebiotech.com for more information.
Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8:30 am CET on December 9, 2014.
